NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer

Published:2014-03 Issue:3 Volume:9 Page:410-413
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ellis Peter M.,Shepherd Frances A.,Laurie Scott A.,Goss Glenwood D.,Olivo Martin,Powers Jean,Seymour Lesley,Bradbury Penelope A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Cancer Facts and Figures 2012;American Cancer Society,2012

2. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer;Shepherd;J Thorac Oncol,2007

3. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress;Chute;J Clin Oncol,1999

4. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung;Feld;J Clin Oncol,1987

5. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group;Murray;J Clin Oncol,1999

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development;Biomedicines;2024-03-02

2. Nanoparticles loaded with pharmacologically active plant-derived natural products: Biomedical applications and toxicity;Colloids and Surfaces B: Biointerfaces;2023-05

3. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification;Lung Cancer;2023-01

4. Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-09

5. Molecular profiles of small cell lung cancer subtypes: Therapeutic implications;Molecular Therapy - Oncolytics;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3